These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31314738)

  • 1. Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma.
    Cannavale K; Xu H; Xu L; Sattayapiwat O; Rodriguez R; Bohac C; Page J; Chao C
    Perm J; 2019; 23():. PubMed ID: 31314738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
    Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
    Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
    Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
    Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
    Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
    PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese physician perception on the treatment of chemotherapy-induced anemia: online cross-section survey study.
    Zhang J; Du Y; Meng Y; Liu X; Mu Y
    Chin Clin Oncol; 2024 Feb; 13(1):5. PubMed ID: 38453656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of cancer chemotherapy-associated anemia in Japan - conditions and issues].
    Yoshino I
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):426-31. PubMed ID: 24743358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
    Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Questionnaire-based survey on chemotherapy-induced anemia.
    Tanaka A; Yoshino I; Makino S; Katsumata N; Takahashi K; Kuwano H; Maehara Y; Nishiyama M
    Int J Clin Oncol; 2014; 19(3):411-20. PubMed ID: 24610155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study.
    Haioun C; Salar A; Pettengell R; Johnsen HE; Duehrsen U; Rossi FG; Verhoef G; Schwenkglenks M; Jaeger U; Hamilton L; Pujol B; Lugtenburg PJ
    Leuk Lymphoma; 2011 May; 52(5):796-803. PubMed ID: 21338278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
    Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
    Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced anemia: the story of darbepoetin alfa.
    Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
    Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End of an era for erythropoiesis-stimulating agents in oncology.
    Schoen MW; Hoque S; Witherspoon BJ; Schooley B; Sartor O; Yang YT; Yarnold PR; Knopf KB; Hrushesky WJM; Dickson M; Chen BJ; Nabhan C; Bennett CL
    Int J Cancer; 2020 May; 146(10):2829-2835. PubMed ID: 32037527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients.
    Lal LS; Raju A; Miller LA; Chen H; Arbuckle R; Sansgiry SS
    Support Care Cancer; 2010 Feb; 19(2):251-9. PubMed ID: 20101414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
    Henry DH; Dahl NV; Auerbach MA
    Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I; Vansteenkiste J
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.